Vimarsana
Biggest News Aggregation in the World

Page 2 - Colitis Center News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Colitis Center. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Colitis Center Today - Breaking & Trending Today

Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders - Vimarsana News

Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders

Bruce Sands, MD, MS.,Dr. Burrill B. Crohn Professor of Medicine, Icahn School of Medicine at Mount Sinai and System Chief, Division of Gastroenter...

Palisade Bio Announces Formation of Clinical Advisory Board - Vimarsana News

Palisade Bio Announces Formation of Clinical Advisory Board

Bruce Sands, MD, MS., Dr. Burrill B. Crohn Professor of Medicine, Icahn School of Medicine at Mount Sinai and System Chief, Division of Gastroenterology,...

Your Irritable Bowel Syndrome (IBS) Holiday Survival Guide - Vimarsana News

Your Irritable Bowel Syndrome (IBS) Holiday Survival Guide

Don’t let irritable bowel syndrome prevent you from enjoying the festive season. Follow these 9 tips to minimize triggers and maximize fun.

IMT Improves Clinical Outcomes in IBD: Meta-Analysis - Vimarsana News

IMT Improves Clinical Outcomes in IBD: Meta-Analysis

Researchers found significant improvements for intestinal microbiota transplant in one type of inflammatory bowel disease but not another.

Adiso Therapeutics Announces the Completion of a Phase 1b Multiple Ascending Dose Study of ADS051 for the Treatment of Moderately-to-Severely Active Ulcerative Colitis - Vimarsana News

Adiso Therapeutics Announces the Completion of a Phase 1b Multiple Ascending Dose Study of ADS051 for the Treatment of Moderately-to-Severely Active Ulcerative Colitis

/PRNewswire/ -- Adiso Therapeutics, Inc., a clinical-stage biotechnology company developing novel medicines targeting chronic inflammatory diseases today...